Home » Topics » BioWorld Science

BioWorld Science
RSS

Merck & Co. reports on L-163689

Aug. 30, 1996

Aldose reductase/5-lipoxygenase inhibitors reported by Tsumura

Aug. 30, 1996

Aldose reductase inhibitors from Terumo

Aug. 30, 1996

Sankyo reports novel hypoglycemic agents

Aug. 30, 1996

Positive efficacy/safety profile for maximal-dose sulfonylurea therapy reported

Aug. 30, 1996

Expanded H-BIG clinical development program announced

Aug. 30, 1996

Yamanouchi reveals 5HT3 agonist

Aug. 30, 1996

Provir effective in patients with travelers' diarrhea

Aug. 30, 1996

FDA approves Helidac for marketing

Aug. 30, 1996

OP-1 role in kidney formation investigated

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...